3 results
Approved WMOCompleted
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Approved WMOPending
The objective of this clinical study is to prove the safety of the CorNeat KPro.
Approved WMOCompleted
To investigate the safety, tolerability and pharmacokinetics after multiple daily doses of YTX-7739